Genetic profiling and tailored therapy in asthma: are we there yet?
Asthma is characterized by reversible bronchial hyper-responsiveness and airway inflammation, and encompasses a wide variety of patients with different clinical phenotypes that display variable responses to therapy. The definition of genomic variation presented in the Human Genome Project has facilitated the development of genetic-guided therapy in various diseases, including asthma. Tailored therapy is a reality in many types of malignancies where specific gene mutations or molecular profiles are identified and used to make critical therapeutic decisions. Despite the identification of beta-adrenergic receptor polymorphisms by Liggett and colleagues during the 1990s, the pharmacogenetics of asthma is still in its infancy. There have been great advances in asthma pharmacogenetics and pharmacotherapy with the completion of several large trials highlighting the effects of genotype on response to asthma therapy. This review focuses on research articles that serve to emphasize the potential role of using genotyping as a tool to develop individualized patient treatment regimens for asthma, thus improving outcomes and limiting adverse effects of certain therapies.
Duke University Medical Center, Division of Pulmonary, Allergy and Critical Care Medicine, PO Box 2629, Durham, NC 27710, USA.
Njira L
NL
Lugogo
Geoffrey S
GS
Ginsburg
Loretta G
LG
Que
D001249:Asthma / Q000188:drug therapy* / Q000235:genetics*; D020869:Gene Expression Profiling; D015894:Genome, Human; D005838:Genotype; D006801:Humans; D010597:Pharmacogenetics / Q000639:trends; D011110:Polymorphism, Genetic; D011943:Receptors, Adrenergic, beta / Q000235:genetics*
D011943:Receptors, Adrenergic, beta